Nama's AI scorecard currently rates Prestige Consumer Healthcare Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PBH's P/E ratio?

Prestige Consumer Healthcare trades at a trailing price-to-earnings ratio of 9.6.

When does PBH report earnings?

Prestige Consumer Healthcare's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.23.

What is the PBH price target?

The median analyst price target from 5 analysts is $70.00, with a range of $55.00 – $75.00.

Is PBH Shariah compliant?

Nama's AAOIFI-style screen reads Prestige Consumer Healthcare as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Prestige Consumer Healthcare (PBH)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Prestige Consumer Healthcare (PBH) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $2.04B, a trailing price-to-earnings ratio of 9.6 and a free-cash-flow yield of 11.8%. Over the most recent reported fiscal year, revenue declined 4.3% and free cash flow per share grew 4.1%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -22.5% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-52.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.04B
Trailing P/E	9.6
Price / book	1.1
Price / sales	1.8
FCF yield	11.8%
Dividend yield	—
Gross margin	53.5%
Operating margin	26.3%
Net margin	15.6%
Revenue growth (YoY)	-4.3%
Revenue growth (3-yr annual)	-1.2%
EPS growth (YoY)	-7.7%
FCF/share growth (YoY)	+4.1%
Beta	0.3
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

PBH earnings

Next report: Feb 4, 2027 (Q3 2027, EPS estimate $1.23). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2027	Nov 5, 2026	$1.13	$1.07	+5.6%	$336.31M
Q1 2027	Aug 6, 2026	$0.98	$0.88	+11.4%	$265.71M
Q4 2026	May 13, 2026	$1.23	$1.39	-11.5%	$281.62M
Q3 2026	Feb 5, 2026	$1.14	$1.16	-1.7%	$283.44M

PBH analyst price target

Median target $70.00 from 5 analysts, ranging $55.00 – $75.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live PBH data on Nama Insights →

Recent Congressional trades

Prestige Consumer Healthcare trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

PBH FAQ

Is PBH a buy?: Nama's AI scorecard currently rates Prestige Consumer Healthcare Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PBH's P/E ratio?: Prestige Consumer Healthcare trades at a trailing price-to-earnings ratio of 9.6.
When does PBH report earnings?: Prestige Consumer Healthcare's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.23.
What is the PBH price target?: The median analyst price target from 5 analysts is $70.00, with a range of $55.00 – $75.00.
Is PBH Shariah compliant?: Nama's AAOIFI-style screen reads Prestige Consumer Healthcare as Not Shariah Compliant. At least one of the three ratios or the industry test failed.